Eyepoint Pharmaceuticals Inc.
EyePoint, Inc. develops advanced bioerodible Durasert E–based ocular therapeutics, leading with DURAVYU (Phase 3 for wet AMD, NPDR, DME) and promising TIE‑2 agonist EYP‑2301, targeting high‑growth retinal disease markets.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Hospitals and Health Care
- Industry: Medical Practices
- Employees: 165
- HQ: Watertown
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.